Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.
Status:
Completed
Trial end date:
2019-02-12
Target enrollment:
Participant gender:
Summary
This is an open label randomised multicentre pre-surgical pharmacodynamics study to compare
and assess the biological effects of AZD9496 and fulvestrant in postmenopausal women with
estrogen receptor (ER) positive (ER+), human epidermal growth factor receptor 2 (HER-2)
negative (HER2-) primary breast cancer.
Patients will receive AZD9496 or fulvestrant and will have an on-treatment image
-guided core biopsy after 5-14 days of commencing treatment.